emerg
reemerg
virus
caus
numer
global
public
health
crise
recent
year
continu
threaten
public
health
secur
outbreak
associ
persontoperson
animaltoperson
transmiss
ebola
middl
eastern
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
sar
pandem
influenza
repres
exampl
grow
problem
virus
often
difficult
protect
due
lack
approv
antivir
drug
vaccin
gener
popul
limit
herd
acquir
immun
provid
protect
infect
addit
caus
acut
infect
high
case
fatal
rate
depend
upon
specif
strain
viru
typic
ebola
merscov
hpai
one
underli
factor
may
contribut
high
fatal
rate
abil
virus
induc
hypercytokinemia
often
term
cytokin
storm
cs
immunocompet
individu
cytokin
storm
potenti
fatal
immun
condit
character
rapidli
prolifer
highli
activ
cell
macrophag
natur
killer
cell
associ
overproduct
releas
inflammatori
cytokin
chemic
mediat
immun
nonimmun
defens
cell
left
untreat
cs
lead
sever
patholog
complic
includ
sepsi
shock
tissu
damag
andor
multipl
organ
failur
edema
ultim
death
furthermor
cs
known
close
associ
develop
viral
hemorrhag
fever
sever
immunopatholog
condit
caus
number
virus
includ
ebola
marburg
lassa
crimeancongo
hemorrhag
fever
dengu
fever
current
futur
develop
treatment
virusinduc
hypercytokinemia
df
virus
despit
sever
potenti
fatal
outcom
follow
infect
virus
cs
seldom
specif
target
order
either
diagnos
andor
potenti
treat
diseas
caus
gener
licens
antivir
drug
emerg
virus
treatment
patient
gener
limit
support
care
fluid
electrolyt
replac
develop
countri
basic
support
care
may
also
absent
although
clinic
present
cs
symptom
markedli
similar
treat
virusinduc
cs
regardless
etiolog
agent
may
challeng
consequ
differ
viru
type
exposur
rout
site
infect
pathogenesi
cytokin
fingerprint
viru
induc
within
host
howev
given
challeng
cs
still
repres
one
truli
broadspectrum
target
therefor
treatment
option
review
discuss
context
respect
viral
diseas
cs
treatment
still
earli
discoveri
phase
better
understand
immunolog
biochem
physiolog
interplay
cs
trigger
virus
expect
result
effect
safer
reatment
option
patient
global
outbreak
emerg
viral
diseas
recent
year
led
improv
understand
cs
specialist
infecti
diseas
along
recognit
import
condit
healthcar
provid
rare
case
treatment
cs
attempt
small
number
patient
howev
exploratori
studi
yield
inconclus
result
vari
therapeut
effect
outcom
highlight
potenti
benefit
challeng
target
immun
respons
treatment
viral
infect
use
strategi
adopt
three
specif
emerg
reemerg
virus
name
ebola
avian
influenza
dengu
review
outlin
sever
treatment
option
util
target
cs
summar
tabl
use
therapeut
strategi
within
experiment
model
infect
within
laboratori
anim
undertaken
human
clinic
set
discuss
h
ighlight
review
highli
virul
influenza
virus
known
caus
aberr
overrespons
immun
respons
link
uncontrol
overexpress
proinflammatori
cytokineschemokin
acut
hypercytokinemia
influenza
virusinduc
cs
gener
manifest
hyperinduct
inflammatori
apoptot
cytokin
infiltr
activ
teffector
cell
fluid
accumul
lung
net
effect
immunolog
physiolog
chang
result
airway
blockag
acut
respiratori
distress
syndrom
ard
multipl
organ
failur
andor
shock
potenti
lead
death
one
earliest
viral
diseas
outbreak
attribut
cs
caus
mortal
associ
infect
spanish
influenza
pandem
pandem
consid
fatal
human
histori
result
loss
million
human
live
worldwid
analysi
agerel
death
rate
pandem
reveal
infect
peopl
year
age
teenag
young
adult
higher
previou
influenza
outbreak
overal
half
influenzarel
death
young
adult
year
age
stark
contrast
mortal
versu
age
curv
observ
season
influenza
strain
preferenti
caus
death
elderli
person
u
nderli
medic
condit
eg
immunocompromis
noteworthi
similar
trend
disproportion
high
incid
death
rate
year
age
group
observ
highli
pathogen
avian
influenza
hpai
viru
outbreak
east
asia
hpai
viru
primarili
found
domest
poultri
wild
migratori
bird
natur
host
reservoir
viru
spread
human
came
close
contact
infect
bird
case
fatal
rate
hpai
one
virul
influenza
virus
surpass
fatal
rate
pandem
influenza
despit
high
fatal
rate
hpai
viru
lack
abil
direct
humantohuman
transmiss
limit
natur
spread
well
number
live
lost
outbreak
although
oseltamivir
given
sever
patient
infect
hpai
hpai
outbreak
southeast
asia
definit
conclus
therapeut
efficaci
deriv
studi
howev
clinic
evalu
suggest
signific
decreas
mortal
antivir
treatment
oseltamivir
cumul
report
studi
suggest
surviv
rate
treat
patient
compar
untreat
patient
lack
signific
increas
surviv
within
treat
patient
may
attribut
time
administr
antivir
treatment
patient
treat
later
stage
infect
presenc
irrevers
pulmonari
damagefailur
futur
scienc
group
current
futur
develop
treatment
virusinduc
hypercytokinemia
special
report
patholog
chang
associ
immun
hyperinduct
like
present
inde
efficaci
oseltamivir
treatment
depend
earli
drug
treatment
administ
surviv
rate
found
patient
treat
within
day
onset
ill
decreas
dministr
commenc
day
order
success
treat
infect
caus
virus
pandem
influenza
combin
strategi
requir
order
reduc
mortal
patient
directli
inhibit
viral
spread
replic
ie
administr
antivir
also
mitig
effect
cs
ie
antiinflammatori
drug
without
imped
natur
abil
fight
infect
collect
approach
repres
promis
approach
reat
viral
infect
number
antiinflammatori
drug
administ
either
monoor
combin
therapi
evalu
treatment
cs
infect
influenza
howev
one
exampl
illustr
therapeut
challeng
associ
administ
antiinflammatori
drug
monotherapi
treat
acut
viral
infect
found
glucocorticoid
treatment
administ
suppress
cytokin
product
protect
mice
lethal
infect
hpia
human
case
studi
outbreak
southeast
asia
patient
treat
steroid
dexamethason
methylprednisolon
without
antivir
drug
oseltamivir
found
high
mortal
rate
steroid
treatment
improv
clinic
outcom
use
inhibitor
celecoxib
mesalazin
monotherapi
combin
antiinfluenza
drug
neuraminidas
inhibitor
zanamivir
also
consid
within
experiment
model
influenza
found
inhibitor
enhanc
antivir
efficaci
zanamivir
treatment
mice
infect
influenza
viru
studi
treatment
administ
h
post
challeng
mimic
time
line
associ
diagnosi
clinic
set
treatment
regimen
use
zanamivir
alon
result
signific
improv
surviv
rate
enhanc
surviv
day
compar
untreat
control
group
surviv
day
zanamivir
alon
reduc
viru
load
lung
inflamm
mortal
similarli
use
inhibitor
alon
celecoxib
mesalazin
provid
improv
surviv
rate
surviv
prolong
surviv
time
day
compar
day
control
howev
infect
mice
treat
tripl
combin
zanamivir
celecoxib
mesalazin
administ
h
post
viru
challeng
signific
improv
surviv
rate
prolong
combin
therapi
antivir
plu
antiinflammatori
drug
zanamivir
plu
inhibitor
oseltamivir
plu
agonist
avian
pandem
influenza
support
therapi
fluid
oxygen
electrolyt
iv
fluid
resuscit
crystalloid
oxygen
therapi
ebola
hsp
heat
shock
protein
nsaid
nonsteroid
antiinflammatori
drug
surviv
time
day
compar
zanamivir
alon
administ
h
postviru
challeng
surviv
day
surviv
time
addit
found
treatment
mice
tripl
drug
combin
also
result
higher
level
lymphocyt
reduc
pulmonari
inflamm
result
studi
suggest
combin
treatment
zanamivir
inhibitor
significantli
improv
surviv
outcom
combin
therapi
provid
synergist
therapeut
outcom
reduc
c
ytokin
dysfunct
prevent
apoptosi
recent
experiment
use
receptor
agonist
suppress
cs
treatment
pathogen
influenza
viru
infect
mice
describ
agonist
specif
aalr
novel
therapi
administ
mice
follow
infect
human
pandem
influenza
found
inhibit
cellular
cytokinechemokin
respons
limit
immunopathogen
damag
well
provid
signific
protect
surviv
mice
otherwis
lethal
viru
challeng
level
protect
higher
compar
treatment
antivir
drug
oseltamivir
surviv
mice
although
combin
therapi
approach
involv
administ
aalr
oseltamivir
provid
highest
level
protect
urviv
rate
mice
mechanist
studi
mice
demonstr
efficaci
agonist
suppress
cs
occur
consequ
system
inhibit
downstream
myeloid
differenti
primari
respons
gene
promot
signal
key
compon
innat
immun
system
identifi
studi
adaptor
molecul
tlr
signal
pathway
respons
primarili
cytokin
amplif
follow
pathogen
influenza
viru
challeng
agonist
aalr
shown
significantli
reduc
releas
inflammatori
cytokin
maintain
protect
antibodi
cytotox
tcell
respons
mice
preclin
data
highlight
promis
drug
treat
acut
viral
infect
suggest
agonist
could
improv
clinic
outcom
significantli
reduc
mortal
patient
infect
highli
pathogen
pandem
influenza
control
fatal
cs
side
effect
diseas
agonist
requir
undergo
futur
develop
lead
safeti
dose
toler
test
phase
clinic
trial
consider
given
use
human
howev
potenti
drug
product
found
good
safeti
profil
compel
justif
candid
drug
taken
forward
full
regulatori
approv
drug
reach
licensur
would
greatli
enhanc
pandem
prepared
influenza
also
potenti
combat
emerg
viral
diseas
induc
cs
eg
ebola
merscov
sar
target
silenc
regulatori
gene
cjun
dnazym
modul
inflamm
influenza
infect
innov
approach
treat
cs
may
encompass
downregul
key
control
genessign
pathway
regul
inflammatori
andor
apoptosi
respons
host
cjun
ntermin
kinas
signal
pathway
involv
regul
numer
cell
activ
includ
prolifer
apoptosi
inflamm
report
activ
influenza
viru
infect
replic
cjun
downstream
molecul
cjun
ntermin
kinas
increas
express
cjun
gene
observ
prolifer
apoptosi
tumorigenesi
infect
influenza
viru
cjun
protein
activ
phosphoryl
form
enhanc
transcript
cytokin
chemokin
rant
contribut
cytokin
overproduct
collect
result
increas
inflamm
dnazym
synthet
singlestrand
dna
design
catalyz
degrad
mrna
complimentari
bind
via
watsoncrick
base
pair
dnazym
cleav
mrna
predetermin
phosphodiest
linkag
dnazym
dz
catalyt
dna
specif
cleav
cjun
mrna
dz
shown
number
preclin
studi
exhibit
antiinflammatori
activ
anim
sepsi
tumor
growth
model
dz
also
shown
safe
well
toler
phase
clinic
test
normal
human
volunt
pilot
studi
use
murin
infect
model
highli
pathogen
avian
influenza
viru
shown
dz
inhibit
cjun
activ
led
improv
protect
surviv
rate
mice
infect
addit
dz
suppress
cjun
also
decreas
tcell
prolifer
proinflammatori
cytokin
express
reduc
viru
titer
tissu
histopatholog
inflammatori
cell
infiltr
futur
scienc
group
current
futur
develop
treatment
virusinduc
hypercytokinemia
special
report
interstiti
edema
lung
taken
togeth
promis
result
show
suppress
key
inflammatori
gene
express
dz
knockdown
cjun
gene
express
potenti
power
strategi
downregul
inflamm
respons
cs
lead
enhanc
protect
therapeut
outcom
sever
highli
fatal
viru
infect
includ
hpia
viru
furthermor
postul
dz
may
broadspectrum
antiinflammatori
effect
also
possibl
explor
whether
approach
downregul
cytokin
overproduct
synergist
therapeut
effect
use
combin
antivir
drug
oseltamivir
zanamivir
howev
anim
studi
warrant
support
concept
shortterm
heat
shock
stress
induc
known
induc
express
heat
shock
protein
hsp
function
molecular
chaperon
protect
cell
multipl
stress
hsp
also
play
import
role
regul
innat
adapt
immun
respons
includ
activ
monocyt
dendrit
cell
macrophag
induc
product
proinflammatori
cytokin
review
shortterm
heat
shock
h
treatment
mice
result
signific
increas
level
key
member
hsp
protein
famili
known
play
role
antivir
immun
level
proinflammatori
cytokin
howev
heat
shocktreat
mice
challeng
lethal
dose
hpai
viru
heat
shocktreat
mice
surviv
viru
challeng
day
postinfect
compar
surviv
untreat
control
group
heat
shocktreat
mice
found
reduc
lung
patholog
damag
reduc
bodi
weight
loss
viru
replic
lung
tissu
found
correl
increas
express
lung
heat
shocktreat
group
compar
control
intriguingli
express
proinflammatori
cytokin
significantli
reduc
day
reduct
presenc
level
also
note
day
postinfect
within
lung
mice
receiv
heat
shock
treatment
compar
untreat
control
group
benefici
effect
heat
shock
treatment
hpai
studi
hypothes
correl
increas
express
protect
effect
also
associ
transient
downregul
overexpress
proinflammatori
c
ytokin
lung
ebola
viru
caus
highli
lethal
hemorrhag
fever
among
deadli
human
pathogen
virul
ebola
viru
zair
strain
case
fatal
rate
highli
fatal
outcom
infect
ebola
zair
strain
human
associ
aberr
innat
respons
character
cs
hypersecret
numer
proinflammatori
cytokin
chemokin
growth
factor
physiolog
effect
induc
cs
thought
lead
dissemin
intravascular
coagul
vascular
dysfunct
collaps
along
multipl
organ
failur
shocklik
syndrom
ssociat
fatal
outcom
ebola
outbreak
african
contin
present
far
infect
peopl
fatal
despit
devast
toll
ebola
human
live
still
approv
antivir
drug
treatment
human
ebola
sever
experiment
drug
evalu
human
patient
emerg
compassion
basi
includ
zmapp
monoclon
antibodi
cocktail
tkmebola
small
interfer
rna
sirna
cocktail
favipiravir
antiinfluenza
drug
review
howev
date
definit
report
highli
effect
therapi
ebola
human
partli
due
fact
standard
random
control
trial
undertaken
drug
administ
compassion
basi
experiment
drug
use
specif
target
ebola
viru
design
treat
immunolog
dysfunct
c
ytokin
overexpress
despit
uncertainti
efficaci
experiment
antivir
therapi
ebola
crisi
reveal
benefici
role
support
therapi
includ
fluid
electrolyt
replac
well
oxygen
therapi
one
studi
guinea
oral
rehydr
given
patient
confirm
ebola
patient
patient
receiv
addit
intraven
fluid
resuscit
median
l
intraven
crystalloid
administ
patient
first
h
admiss
patient
receiv
support
therapi
mortal
rate
patient
case
fatal
rate
lower
record
site
guinea
anoth
retrospect
studi
ebola
patient
sierra
leon
document
case
fatal
rate
highqual
support
care
thought
contribut
higher
number
survivor
observ
guinea
random
control
studi
need
affirm
therapeut
role
support
therapi
fluid
electrolyt
replac
mprove
urviv
treatment
ebola
patient
thought
gener
support
care
therapi
includ
fluid
rehydr
electrolyt
replac
may
mitig
hemorrhag
septic
shock
reduc
multipl
organ
failur
clinic
manifest
associ
detriment
effect
cytokin
immunolog
dysfunct
follow
support
therapi
may
play
benefici
role
reduc
clinic
damag
induc
cs
number
studi
involv
varieti
experiment
drug
suppress
cytokin
undertaken
animalcel
cultur
infect
model
ebola
includ
myxomavirusderiv
serpin
pyridinyl
imidazol
inhibitor
mapk
myxomaviru
envelop
dna
viru
belong
poxvirida
famili
caus
fatal
myxomatosi
rabbit
evad
host
immun
respons
caus
patholog
damag
viru
produc
number
extracellular
protein
protect
viru
destruct
host
antivir
immun
respons
one
protein
potent
inhibitor
thrombolyt
thrombot
proteas
demonstr
antiinflammatori
properti
wide
rang
anim
model
small
exploratori
studi
wildtyp
balbc
mice
infect
mouseadapt
ebola
viru
zair
mayinga
strain
treat
found
increas
surviv
timer
dose
depend
higher
drug
concentr
offer
higher
protect
furthermor
treat
anim
found
decreas
tissu
necrosi
cell
invas
spleen
liver
compar
untreat
infect
mice
addit
noteworthi
purifi
protein
demonstr
antiinflammatori
activ
anim
model
vascular
injuri
highlight
potenti
broader
therapeut
util
preliminari
find
may
provid
import
insight
whether
reduc
inflammatori
tissu
damag
mediat
ebola
viru
result
improv
therapeut
outcom
support
larger
scale
preclin
studi
determin
whether
use
treat
ebola
virusinduc
death
larger
anim
model
includ
guinea
pig
nonhuman
p
rimat
ebola
viru
target
antigen
present
cell
includ
macrophag
dendrit
cell
process
also
activ
mapk
signal
pathway
mapk
signal
pathway
play
essenti
role
immun
evas
induct
deregul
immun
respons
present
attract
target
downregul
inflammatori
enhanc
antivir
respons
infecti
virus
ebola
viru
target
infect
antigenpres
cell
effect
knock
type
interferon
product
upregul
product
number
proinflammatori
cytokin
includ
other
combin
effect
result
impair
innat
immun
respons
enhanc
viral
replic
host
number
mapk
chemic
inhibitor
identifi
test
monocytederiv
dendrit
cell
abil
inhibit
ebola
viru
infect
andor
cytokin
overproduct
inde
pyridinyl
imidazol
inhibitor
found
reduc
ebola
viru
replic
pmadifferenti
human
cell
andor
primari
monocytederiv
dendrit
cell
furthermor
product
number
cytokin
includ
found
inhibit
dosedepend
manner
furthermor
number
chemokin
associ
fatal
outcom
human
exampl
rant
also
found
reduc
recent
public
suggest
repurpos
gener
nonspecif
antiinflammatori
therapi
ibuprofen
could
also
use
prevent
treatment
ebola
howev
propos
ibuprofen
may
work
destabil
glycoprotein
viru
therebi
prevent
viru
attach
cellular
entri
addit
studi
warrant
determin
whether
potenti
dual
action
ibuprofen
glycoprotein
destabil
establish
antiinflammatori
demonstr
signific
therapeut
benefit
within
experiment
anim
model
nfection
andor
within
human
case
ebola
infect
mosquitoborn
dengu
viru
progress
asymptomat
phase
term
df
sever
form
dengu
hemorrhag
fever
dhf
shock
syndrom
left
untreat
inflammatorydriven
respons
sepsi
death
first
infect
four
serotyp
dengu
viru
devi
devv
major
case
tend
asymptomat
mild
complicafutur
scienc
group
current
futur
develop
treatment
virusinduc
hypercytokinemia
special
report
tion
aris
individu
subsequ
reinfect
differ
serotyp
dev
diseas
becom
sever
lead
potenti
fatal
dhf
dengu
shock
syndrom
patient
sever
form
dengu
serum
level
sever
cytokin
includ
elev
sever
diseas
thought
direrctli
link
increas
inflammatori
cytokin
aberr
cytokin
level
known
associ
increas
incid
develop
dhf
thu
suppress
cytokin
level
use
approach
improv
therapeut
outcom
dengu
patient
small
pilot
studi
doxycyclin
tetracyclin
evalu
effect
modul
inflammatori
cytokin
patient
dhf
df
random
studi
serum
level
variou
cytokin
doxycyclineor
tetracyclinetr
dengu
patient
compar
untreat
control
patient
patient
receiv
doxycyclin
tetracyclin
treatment
demonstr
signific
reduct
serum
level
compar
untreat
control
patient
downregul
cytokin
observ
persist
continu
day
day
follow
treatment
furthermor
doxycyclin
found
effect
tetracyclin
modul
proinflammatori
cytokin
result
greater
reduct
serum
cytokin
l
evel
mechan
doxycyclin
modul
inflammatori
cytokin
patient
infect
df
viru
complet
understood
doxycyclin
antibiot
belong
class
tetracyclin
known
possess
known
immunomodul
effect
includ
reduc
serum
level
proinflammatori
cytokin
patient
multipl
sclerosi
rheumatoid
arthriti
doxycyclin
also
found
abl
inhibit
dengu
viru
replic
cell
cultur
hypothes
interact
dengu
viru
e
protein
inhibit
conform
chang
requir
viru
entri
target
cell
clinic
studi
need
futur
determin
whether
treatment
doxycyclin
provid
signific
therapeut
outcom
df
dhf
dss
patient
evalu
diseas
sever
surviv
rate
decreas
requir
durat
hospit
furthermor
worthwhil
small
exploratori
studi
determin
whether
doxycyclin
provid
benefici
therapeut
effect
virusinduc
hemorrhag
fever
although
therapeut
benefit
antibiot
treatment
must
weigh
potenti
risk
associ
use
includ
rise
antibiot
resist
interestingli
use
antibiot
use
support
antimicrobi
therapi
ebola
patient
guinea
direct
effect
antibiot
reatment
studi
known
zika
viru
import
emerg
mosquitoborn
flaviviru
caus
larg
epidem
south
america
caribbean
island
human
infect
zika
fever
less
sever
compar
dhf
df
pathogenesi
associ
polyfunct
tcell
activ
involv
elev
sever
serum
cytokin
acut
infect
phase
signific
increas
serum
cytokin
concentr
protein
rant
compar
normal
control
late
recoveri
phase
level
found
highest
sinc
df
zika
virus
mosquitoborn
flavivirus
spread
vector
aed
aegypti
mosquito
share
similar
immunopathogenesi
pattern
tcell
activ
inflammatori
cytokin
induct
propos
lesson
learn
dengu
research
may
expedit
develop
effect
therapeut
prophylact
strategi
zika
viru
conclus
futur
perspect
mani
infecti
diseas
public
health
expert
predict
zoonot
mosquitoborn
virus
continu
emerg
reemerg
increas
frequenc
futur
novel
virus
continu
evolv
natur
occur
mutat
pose
realist
threat
global
public
health
well
signific
impact
economi
mani
emerg
novel
virus
like
hard
protect
due
lack
approv
antivir
drug
vaccin
avail
therefor
prepared
identif
newnovel
treatment
therapeut
strategi
essenti
futur
public
health
perspect
particular
develop
approach
target
common
event
pathway
use
pathogen
virus
induct
cs
offer
potenti
treatment
effectic
across
differ
viral
famili
andor
strain
worldwid
outbreak
abl
deepen
scientif
understand
emerg
virus
induc
cs
improv
knowledg
respect
complex
interplay
host
antivir
immun
respons
viru
abil
modifi
respons
caus
immun
dysfunct
critic
identifi
new
special
report
wong
viswanathan
wang
sun
clark
delia
effect
therapi
treat
acut
infect
caus
mani
emerg
virus
envisag
increas
understand
lead
better
treatment
option
address
mortal
morbid
caus
cs
effect
cs
coupl
acut
viral
infect
host
complex
overwhelm
potenti
fatal
host
promis
therapeut
option
mitig
treat
cs
highlight
review
list
figur
like
effect
treatment
strategi
virusinduc
cs
comprehens
wellbalanc
strategi
effect
downregul
inflammatori
cytokin
reduc
apoptosi
tissu
damageinjuri
ultim
restor
natur
antivir
immun
respons
maintain
physiolog
homeostasi
bodi
figur
use
drug
monotherapi
may
insuffici
achiev
outcom
howev
like
success
treatment
human
patient
infect
csinduc
emerg
viru
need
encompass
use
twoor
threeprong
therapeut
strategi
involv
antivir
drug
avail
alongsid
adjunct
biolog
chemic
immunemodul
agent
suppress
cs
support
therapi
fluid
e
lectrolyt
replac
andor
oxygen
therapi
current
futur
develop
treatment
virusinduc
hypercytokinemia
special
report
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
includ
employ
consult
honoraria
stock
ownership
option
expert
testimoni
grant
patent
receiv
pend
royalti
write
assist
util
product
manuscript
cytokin
storm
import
underli
caus
mortal
patient
infect
sever
emerg
virus
ebola
marburg
middl
eastern
respiratori
syndrom
coronaviru
merscov
pandem
influenza
other
current
standard
therapi
treat
cytokin
storm
cs
drug
approv
specif
treat
cs
clinic
result
report
use
corticosteroid
nonsteroid
antiinflammatori
drug
adjunct
therapi
antivir
drug
treat
cs
induc
pandem
influenza
virus
far
shown
inconclus
thu
requir
random
control
studi
number
experiment
treatment
option
current
preclin
test
hope
lead
drug
candid
proven
clinic
safe
efficaci
result
first
drug
specif
design
treat
cytokin
storm
like
treatment
emerg
viru
infect
need
entail
use
antivir
drug
conjunct
immunemodul
agent
suppress
cs
aid
support
therapi
